Rohto Japan's First OTC Maker To Enter Regenerative Medicines Market
This article was originally published in PharmAsia News
Rohto Pharmaceutical has joined Astellas Pharma and other Japan drug makers in looking into regenerative medicines as the domestic market for that class expects to reach a $2 billion value by 2020.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.